





#### Fax Completed Form To 1.833.404.2392 Prescriber Help Desk

1.833.587.2012

#### **Online**

covermymeds.com/main/ prior-authorization-forms/

### **Request for Prior Authorization DIRECT ORAL ANTICOAGULANTS**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	B					
	Patient name			DOB		
Patient address						
	Prescriber name			Phone		
Prescriber address				Fax		
Pharmacy name	Address			Phone		
Prescriber must complete all informa	 ation above. It must be legible, o	orrect, and com	plete or f	_ orm will∣	be returned	
Pharmacy NPI	Pharmacy fax		IDC			
dosing and length of therapy for recommended dose will not be indications for the requested dr age for indication; and 2) Patien active bleeding; and 4) For a dia of at least one additional risk fac	considered. Payment will by under the following const does not have a mechaning nosis of atrial fibrillation	oe considered ditions: I) P cal heart valv or stroke pre	for FDA atient is ve; and 3 vention,	A appro within b) Patien patien	oved or co the FDA I nt does no	mpendia abeled ot have
5) A recent creatinine clearance Patient's current body weight is at a therapeutic dose with at leaprescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is p	e (CrCl) is provided; and 6) is provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial therafractionated heparin) is pr	A recent Chas document and 9) For re (T) or pulmon upy with a pan ovided. The r	ild-Pugh ation of equests f nary em renteral equired	n score if a trial if or edox bolism anticoa trials n	and thera kaban, who (PE), agulant (lo nay be ove	py failure en w erridden
Patient's current body weight is at a therapeutic dose with at lea prescribed for the treatment of documentation patient has had molecular weight heparin or un	e (CrCl) is provided; and 6) is provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial therafractionated heparin) is pr	A recent Chas document and 9) For re (T) or pulmon upy with a pan ovided. The r	ild-Pugh cation of equests f nary em renteral equired ould be r	n score i a trial i for edox bolism anticoa trials n nedicall	and thera kaban, who (PE), agulant (lo nay be ove ly contrain	py failure en w erridden
Patient's current body weight is at a therapeutic dose with at lea prescribed for the treatment of documentation patient has had molecular weight heparin or un when documented evidence is p	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial thera fractionated heparin) is provided that the use of the	A recent Chas document and 9) For re (T) or pulmon apy with a pan ovided. The re ese agents wo	ild-Pugh cation of equests f nary em renteral equired ould be r	n score i a trial i for edox bolism anticoa trials n nedicall	and thera kaban, who (PE), agulant (lo nay be ove ly contrain	py failure en w erridden
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is perferred	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial thera fractionated heparin) is provided that the use of the	A recent Chas document and 9) For re (T) or pulmon apy with a pan ovided. The re ese agents wo	ild-Pugh cation of equests f nary em renteral equired ould be r	n score if a trial if or edox bolism anticoa trials medicall	and thera kaban, who (PE), agulant (lo nay be ove ly contrain	py failure en w erridden
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is part of the part of th	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial thera fractionated heparin) is provided that the use of the	A recent Chas document and 9) For read of the control of the contr	ild-Pugh cation of equests f nary em renteral required ould be r	n score if a trial if or edox bolism anticoa trials nedicall	and thera kaban, who (PE), agulant (lo nay be ove ly contrain	py failure en w erridden ndicated.
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is part of the part of th	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial thera fractionated heparin) is provided that the use of the	A recent Chas document and 9) For read and 9)	ild-Pugh cation of equests f nary em renteral required ould be r	n score if a trial if or edox bolism if anticoal trials in medicalling require	and thera kaban, who (PE), agulant (lo nay be ove ly contrained)	py failure en w erridden ndicated.
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is possible.  Preferred (no PA required if within establication in the prescribed in the prescrib	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial thera fractionated heparin) is provided that the use of the	A recent Chas document and 9) For read and 9)	ild-Pugh cation of equests f nary em renteral equired ould be r red (PA	n score if a trial if or edox bolism if anticoal trials in medicalling require	and thera kaban, who (PE), agulant (lo nay be ove ly contrain ed)  Savaysa  Xarelto Sus	py failure en w erridden ndicated.
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is part of the part of th	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial therafractionated heparin) is provided that the use of the ished quantity limits)	A recent Che las document and 9) For recent (T) or pulmon upy with a particular with a particular with a particular and Dabigatra   Dabigatra   Pradaxa	ild-Pugh cation of equests f nary em renteral equired ould be r red (PA	n score if a trial if or edox bolism anticoal trials nedicall require	and thera kaban, who (PE), agulant (lo nay be ove ly contrain ed)  Savaysa  Xarelto Sus	py failure en w erridden ndicated.
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is part of the part of th	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial thera fractionated heparin) is provided that the use of the ished quantity limits)  Dosage Instructions	A recent Che las document and 9) For recent (T) or pulmon upy with a particular with a particular with a particular and Dabigatra   Dabigatra   Pradaxa	ild-Pugh cation of equests f nary em renteral equired ould be r red (PA	n score if a trial if or edox bolism anticoal trials nedicall require	and thera kaban, whe (PE), agulant (lo nay be ove ly contrain ed)  Savaysa Xarelto Sus	py failure en w erridden ndicated.
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is possible.  Preferred (no PA required if within establication in the prescribed in the prescrib	e (CrCl) is provided; and 6) s provided; and 8) Patient has two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial therafractionated heparin) is provoided that the use of the ished quantity limits)  Dosage Instructions	A recent Chas document and 9) For recent (T) or pulmon upy with a particle of the recent agents were agents	ild-Pugh cation of equests that yementeral required build be reduired ould be reduired (PA	n score if a trial if or edox bolism anticoal trials nedicall require	and thera kaban, whe (PE), agulant (lo nay be ove ly contrain ed)  Savaysa Xarelto Sus	py failure en w erridden ndicated.
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is possible.  Preferred (no PA required if within establication in the prescribing in the prescribed in the prescribing in the prescribed in the prescribing in the prescr	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial thera fractionated heparin) is provided that the use of the ished quantity limits)  Dosage Instructions  eart valve?	A recent Chas document and 9) For recent (T) or pulmon upy with a particle agents were agents ag	ild-Pugh cation of equests f nary em renteral required ould be r red (PA  Oral Pack y  No  No	n score Ta trial Ta trial Tor edox bolism anticoa trials n nedical Tequire  Cet Days Su Diag	and thera kaban, whe (PE), agulant (lo nay be ove ly contrain ed)  Savaysa Xarelto Sus	py failure en w erridden ndicated.
Patient's current body weight is at a therapeutic dose with at lead prescribed for the treatment of documentation patient has had molecular weight heparin or unwhen documented evidence is particular.  Preferred (no PA required if within establication in Pradaxa Capsules  Strength  Does patient have mechanical here.	e (CrCl) is provided; and 6) s provided; and 8) Patient hast two preferred DOACs; deep vein thrombosis (DV 5 to 10 days of initial therafractionated heparin) is provided that the use of the ished quantity limits)  Dosage Instructions  eart valve?	A recent Chas document and 9) For recent (T) or pulmon upy with a particle agents were agents age	ild-Pughtation of equests for ary emerceral required build be red (PA  an Oral Pack y No No Dobtained	n score a trial for edox bolism anticoa trials n nedicall require  Days StDiag	and thera kaban, who (PE), agulant (lo nay be ove ly contrain ed)  Savaysa  Xarelto Sus  upply gnosis:	py failure en w erridden ndicated.

Page I of 2 (Rev 1/24)

Provide recent Child-Pugh score: \_

Date completed:







Score

# Request for Prior Authorization DIRECT ORAL ANTICOAGULANTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

**Risk Factors** 

Risk factor based CHA<sub>2</sub>DS<sub>2</sub>-VASc Score

Fax Completed Form To 1.833.404.2392 Prescriber Help Desk

Prescriber Help Desk 1.833.587.2012

**Online** 

covermymeds.com/main/ prior-authorization-forms/

## Requests for a diagnosis of atrial fibrillation or stroke prevention:

	Congestive heart failure	I			
	Hypertension	I			
	☐ Age ≥ 75 years	2			
	Age between 65 and 74 years	I			
	Stroke / TIA / TE	2			
	Vascular disease (previous MI, peripheral arterial disease or aortic plaque)	I			
	☐ Diabetes mellitus	I			
	Female	I			
	т	otal			
Document 2 preferred D	OAC trials:	•	_		
Preferred DOAC Trial I: N	ame/Dose:	Trial Dates:			
Failure reason:					
Preferred DOAC Trial 2: N	ame/Dose:	Trial Dates:			
Failure reason:					
Requests for edoxaban (	Savaysa):				
Provide documentation of 5 or unfractionated heparin) for	to 10 days of initial therapy with a parenteral or diagnosis of DVT or PE:	anticoagulant (lo	w molecular weight heparin		
Drug name & dose:		Trial dates:			
Medical or contraindication	reason to override trial requirements:				
Attach lab results and oth	er documentation as necessary.				
Prescriber signature (Must mat	ch prescriber listed above.)	Date of subr	nission		

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

(Rev 1/24) Page 2 of 2